Dylan is doing well, he finished the Perifosine/Temsirolimus study after 8 weeks and his work up scans showed a stable result, with no change to his cancer. We decided to cease the study due to the intense leg pain that Dylan experienced and because it did not appear to do anything positive for him. We are now on a new clinical trial, which involves an infusion once a week. This study is a Phase II called IMC-A12 Anti-IGF-I Receptor Monoclonal Antibody. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. IMC-A12 blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Dylan appears to be tolerating this treatment well, his only side effects are a decreased appetite and body itching in the evenings.
Dylan had a visit from his God Father Grant, who came to
Cain is doing great, he played at